We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Compugen Announces Second Diagnostic Agreement with Biosite Incorporated

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Compugen Ltd. has announced a second agreement with Biosite Incorporated for the development and commercialization of immunoassay diagnostic products.

Under the new agreement, in addition to expanding the number of potential diagnostic biomarkers available for selection by Biosite, Biosite obtains access to Compugen's increasing inventory of immunoassay biomarkers. Furthermore, the collaboration is expanded to cover cardiovascular, oncology and additional diagnostic areas.

As with the initial agreement, Compugen will receive milestone payments and royalties from the sale of any products emerging from the collaboration. Compugen retains the exclusive right to therapeutic applications of both the targets and associated antibodies.

The collaboration combines Biosite's expertise in both rapid, high-affinity antibody development and commercialization of proprietary testing platforms for single and multiple biomarker assays with Compugen's discovery capabilities based on its predictive analysis of the human proteome and related discovery engines.

“Targeting our goal of becoming the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry, we must not only enter into new collaborations, but also build on and strengthen our existing ones,” said Alex Kotzer, President and Chief Executive Officer of Compugen.

“Therefore, we are very pleased with this significant expansion of our immunoassay diagnostic collaboration with Biosite, a leading provider of rapid diagnostic products and antibody development technologies,” he said.